Introduction Alzheimer's disease and related dementias (ADRD) disproportionately impact
racial and ethnic minority and socioeconomically disadvantaged adults. Yet, these …

Debate exists regarding differences in the prevalence of Alzheimer disease (AD) in African
Americans and Hispanics in the United States, with some evidence suggesting that the …

Introduction Although dementia prevalence differs by race, it remains unclear whether
cognition and neuropsychiatric symptom severity differ between Black and White individuals …

Abstract Purpose of the Study: The goal of the study was to examine barriers and facilitators
to clinical research participation among African Americans, as well as recommendations for …

We found no studies in the United States that explored research participants' perspectives
about sharing their qualitative data. We present findings from interviews with 30 individuals …

Alzheimer disease (AD) research faces challenges to successful enrollment, especially to
clinical trials and biomarker studies. Failure to recruit the planned number of participants in a …

It is well known that vascular factors and specific social determinants of health contribute to
dementia risk and that the prevalence of these risk factors differs according to race and sex …

Introduction Alzheimer's disease (AD) incidence is disproportionately high in African
Americans, yet, recruitment of this community to AD clinical trials is challenging. Methods We …

consults for Eli Lilly, Impax, Zosano, and Biohaven; receives research funding from Amgen
and eNeura and personal compensation for medical-legal consulting; and has received …

Abstract The Washington University School of Medicine Knight Alzheimer Disease Research
Center's “African American Participation in Alzheimer Disease Research: Effective …